EMA PRIME Scheme Stays Selective, Granting Access to Two Gene Therapies in July 2026

The July 2026 review by the Committee for Medicinal Products for Human Use illustrates the stringent selectivity of PRIME scheme eligibility, which granted approval to only two of seven advanced therapy medicinal products while rejecting the remainder on grounds of insufficient demonstration of major therapeutic advantage.

PRIME Scheme Eligibility Outcomes

Both approved candidates were adeno-associated viral vector-based gene therapies directed at rare inherited retinal dystrophy and Parkinson’s disease, underscoring the scheme’s emphasis on conditions with clear unmet medical need. Cumulative data through mid-2026 confirm that roughly one-quarter of all applications succeed, with oncology and neurology generating the largest volumes of both approvals and rejections. This pattern reveals how PRIME scheme eligibility continues to favor therapies that can articulate precise advantages early in development.

Two-Part Evaluation Framework

Eligibility determinations rest on a two-part framework that first verifies the absence of satisfactory diagnostic, preventive, or therapeutic options in the European Union or the presence of potential major therapeutic advantage, then evaluates whether submitted data credibly project meaningful clinical outcome improvements. The Committee for Medicinal Products for Human Use applies these standards at an earlier developmental stage than accelerated assessment yet employs identical substantive thresholds, enabling consistent comparison across exploratory and confirmatory evidence packages. This approach supports conclusions about scheme performance by separating data maturity from the strength of the clinical signal and the precision with which unmet need is articulated.

Ad

Evidence from July 2026 Submissions

All seven products reviewed in July 2026 presented non-clinical plus exploratory clinical data, yet only the two adeno-associated viral vector candidates met the threshold for demonstrated potential advantage, indicating that data volume alone does not determine outcome. Small- and medium-sized enterprises accounted for three of the five rejections despite submitting the largest absolute number of requests historically, revealing a persistent disparity in success rates relative to larger sponsors. Oncology programmes continue to dominate both applications and denials, reflecting the challenge of establishing incremental benefit against rapidly evolving standards of care at an early stage.

Strategic Guidance for Sponsors

Developers must calibrate application timing to coincide with sufficiently robust exploratory signals rather than minimal proof-of-concept data, particularly in competitive indications where existing therapies already address substantial portions of unmet need. Small- and medium-sized enterprises may benefit from formal early-entry designation and confirmed small- and medium-sized enterprise status to access fee reductions and structured support that could narrow the observed success gap. Because PRIME scheme eligibility does not automatically confer accelerated assessment at marketing authorisation, sponsors should integrate continuous regulatory engagement and iterative data strengthening into market-access planning to maximise the scheme’s downstream value for pricing and reimbursement negotiations.